ATP-Citrate Synthase (ACLY) Antibody
169€ (20 µg)
Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.
935106861
info@markelab.com
name
ATP-Citrate Synthase (ACLY) Antibody
category
Primary Antibodies
provider
Abbexa
reference
abx301912
tested applications
ELISA, WB, IHC, IF/ICC
Description
ACLY Antibody is a Rabbit Polyclonal against ACLY.
Documents del producto
Instrucciones
Data sheet
Product specifications
| Category | Primary Antibodies |
| Immunogen Target | ATP-Citrate Synthase (ACLY) |
| Host | Rabbit |
| Reactivity | Human |
| Recommended Dilution | WB: 1/500 - 1/5000, IHC: 1/20 - 1/200, IF/ICC: 1/50 - 1/200. Optimal dilutions/concentrations should be determined by the end user. |
| Clonality | Polyclonal |
| Conjugation | Unconjugated |
| Isotype | IgG |
| Purity | > 95% |
| Purification | Purified by Protein G. |
| Size 1 | 20 µg |
| Size 2 | 50 µg |
| Size 3 | 100 µg |
| Size 4 | 200 µg |
| Size 5 | 1 mg |
| Form | Liquid |
| Tested Applications | ELISA, WB, IHC, IF/ICC |
| Buffer | 0.01 M PBS, pH 7.4, 0.03% Proclin-300 and 50% Glycerol. |
| Availability | Shipped within 5-10 working days. |
| Storage | Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles. |
| Dry Ice | No |
| UniProt ID | P53396 |
| Gene ID | 47 |
| NCBI Accession | NP_001087.2, NM_001096.2 |
| OMIM | 108728 |
| Alias | ACL,ATPCL,CLATP |
| Background | Antibody anti-ACLY |
| Status | RUO |
Descripción
ATP-Citrate Synthase (ACLY) is a cytoplasmic enzyme that catalyzes the conversion of citrate and CoA into acetyl-CoA and oxaloacetate, a reaction powered by ATP hydrolysis. ACLY is a central player in cellular metabolism, linking energy production in the mitochondria with fatty acid and cholesterol biosynthesis. Acetyl-CoA generated by ACLY serves as a precursor for lipid synthesis and is essential for protein acetylation, including histone acetylation, which regulates gene expression. ACLY activity is upregulated in cancer cells to support rapid cell proliferation and metabolic reprogramming, making it a target for cancer therapy. Dysregulation of ACLY is also associated with metabolic diseases such as obesity, insulin resistance, and hyperlipidemia.
Related Products
Human ACLY(ATP-citRate synthase) ELISA Kit
Ver Producto
Mouse Acly(ATP-citRate synthase) ELISA Kit
Ver Producto